Stock listing

NASDAQ:BFRI Biofrontera Inc. Stock

Home listing (NASDAQ) of Biofrontera Inc.

Follow Biofrontera Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BFRI

$0.53 USD -0.07 (-11.6%)

Close on Nov 20, 2026

Past year -29.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.53 – $0.588 USDNov 20, 2026
Volume
195,905 sharesNov 20, 2026
Market cap
$9.51M USDAt the close on Nov 20, 2026 · price × 17.95M shares outstanding
52-week range
$0.53 – $1.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$537,536 USDMedian day 302,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Biofrontera Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BFRI · Home$0.53 USD-0.07 (-11.6%)195,905$0.57$0.588$0.53$0.60Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BFRI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.53-0.07-11.6%$0.57$0.588$0.53195,905
$0.60+0.006+1.1%$0.602$0.66$0.581130,932
$0.593+0.023+4.1%$0.55$0.675$0.541197,341
$0.57-0.13-18.6%$0.70$0.70$0.57401,738
$0.70-0.226-24.4%$0.96$0.96$0.683876,000
$0.926-0.012-1.3%$0.938$0.94$0.912131,400
$0.938+0.01+1.1%$0.94$0.94$0.90105,800
$0.928+0.04+4.5%$0.90$0.94$0.888156,700
$0.888+0.06+7.2%$0.84$0.907$0.81229,600
$0.828+0.02+2.5%$0.82$0.84$0.81208,100
$0.808-0.096-10.6%$0.906$0.907$0.80148,600
$0.904+0.014+1.6%$0.889$0.93$0.845194,200
$0.89+0.02+2.3%$0.90$0.901$0.85269,500
$0.87-0.003-0.3%$0.873$0.95$0.85475,900
$0.873-0.059-6.3%$0.94$0.94$0.849302,400
$0.932+0.046+5.2%$0.864$0.95$0.864145,600
$0.886+0.046+5.5%$0.849$0.886$0.815141,800
$0.84+0.018+2.2%$0.847$0.863$0.80194,300
$0.822+0.033+4.2%$0.79$0.826$0.78110,000
$0.789+0.008+1.0%$0.799$0.812$0.78112,900
$0.781-0.019-2.4%$0.83$0.83$0.781160,100
$0.80-0.004-0.5%$0.80$0.81$0.80130,300
$0.804-0.002-0.2%$0.823$0.83$0.8071,900
$0.806-0.016-1.9%$0.85$0.85$0.79150,600
$0.822-0.025-3.0%$0.881$0.92$0.822203,700
$0.847+0.017+2.0%$0.82$0.882$0.82275,900
$0.83-0.062-7.0%$0.885$0.89$0.82347,400
$0.892-0.033-3.6%$0.927$0.94$0.87319,700
$0.925-0.045-4.6%$0.973$1.00$0.925140,200
$0.97+0.051+5.5%$0.925$1.01$0.91275,200
$0.919-0.016-1.7%$0.936$0.95$0.882231,600
$0.935+0.003+0.3%$0.924$0.98$0.91278,800
$0.932+0.041+4.6%$0.88$0.948$0.86390,300
$0.891-0.124-12.2%$1.00$1.00$0.88720,900
$1.015-0.025-2.4%$1.11$1.12$1.00334,700
$1.04-0.04-3.7%$1.06$1.07$1.02340,900
$1.08-0.01-0.9%$1.11$1.14$1.07284,000
$1.09-0.04-3.5%$1.10$1.14$1.08258,100
$1.13-0.05-4.2%$1.16$1.17$1.09383,800
$1.18-0.02-1.7%$1.20$1.23$1.16247,100
$1.20+0.05+4.3%$1.16$1.225$1.14280,500
$1.15-0.02-1.7%$1.17$1.18$1.122288,900
$1.17+0.01+0.9%$1.16$1.18$1.11476,300
$1.16-0.16-12.1%$1.32$1.32$1.14918,800
$1.32+0.08+6.5%$1.29$1.33$1.27376,200
$1.24+0.03+2.5%$1.22$1.29$1.22573,400
$1.21+0.02+1.7%$1.22$1.24$1.18384,600
$1.19-0.17-12.5%$1.33$1.36$1.171,476,600
$1.36-0.19-12.3%$1.57$1.57$1.3552,365,600
$1.55+0.09+6.2%$1.54$1.62$1.501,456,100
$1.46-0.08-5.2%$1.53$1.555$1.361,645,700
$1.54-0.02-1.3%$1.57$1.61$1.525532,900
$1.56-0.05-3.1%$1.64$1.66$1.54840,200
$1.61+0.10+6.6%$1.52$1.63$1.52631,300
$1.51-0.01-0.7%$1.51$1.559$1.48549,500
$1.52-0.015-1.0%$1.525$1.60$1.50581,200
$1.535+0.005+0.3%$1.54$1.56$1.505400,700
$1.53-0.06-3.8%$1.555$1.60$1.50744,300
$1.59+0.10+6.7%$1.53$1.61$1.51837,000
$1.49-0.04-2.6%$1.555$1.57$1.475436,200
$1.53+0.02+1.3%$1.54$1.60$1.49542,900
$1.51+0.05+3.4%$1.47$1.52$1.42439,887
$1.46-0.02-1.4%$1.48$1.55$1.41995,019
$1.480.000.0%$1.48$1.52$1.441446,300
$1.48+0.06+4.2%$1.43$1.50$1.40526,100

Splits

1 split · NASDAQ:BFRI · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:BFRI
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Biofrontera Inc. news

Biofrontera Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
21 in the last 12 months · 138 in all · newest Nov 13, 2026 · oldest 2021
Calls
22 calls with a replay · 22 with a transcript · latest Nov 13, 2026

Where Biofrontera Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BFRI · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BFRIBOATSUnited StatesUSD
gettex:AI10gettexGermanyEUR
Munich:AI10MunichGermanyEUR
LS Exchange:A3EFRZLS ExchangeGermanyEUR

Valuation

EV/sales 0.3× against a median of 0.6×: 4th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$13.83M USD
P/E
Loss
EV/sales
0.3×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
84.6%
Operating margin
−14.1%
Net margin
−12.7%
Debt to equity
Negative equity
Beta vs S&P 500
1.96

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Biofrontera Inc. · NASDAQ:BFRIUS$9.51MUS$13.83Mn/a0.3×n/an/a−12.7%n/a1.96
Botanix Pharmaceuticals Limited · ASX:BOTUS$14.62MUS$133,810n/a0.0×n/a0.3×−202.2%0.2×n/a
Bal Pharma Limited · NSE:BALPHARMAUS$14.30MUS$14.30M18.4×0.4×3.9×1.6×2.1%0.0×n/a
Daesung Microbiological Laboratories Co., Ltd. · KRX:036480US$14.23MUS$18.69M54.3×1.0×13.5×0.6×1.4%0.4×n/a
Turk Ilac ve Serum Sanayi AS · BIST:TRILCUS$14.16MUS$22.15M7.7×0.2×0.6×0.4×1.6%0.2×n/a
PT Phapros Tbk · IDX:PEHAUS$12.79MUS$41.58M4.5×0.7×4.6×0.5×5.0%1.5×n/a
PT Ikapharmindo Putramas Tbk · IDX:IKPMUS$11.81MUS$10.76Mn/an/an/a0.9×n/a0.0×n/a
Alpa Laboratories Limited · NSE:ALPAUS$11.33MUS$11.33M24.0×0.9×12.2×0.6×3.8%0.0×n/a
Advicenne SA · EURONEXT:ALDVIUS$10.53MUS$32.08Mn/a4.9×n/an/a−158.7%n/an/a
Optimi Health Corp. · CSE:OPTIUS$9.18MUS$67,058n/a0.6×n/a0.8×n/a0.0×1.08
ChoA Pharmaceutical Co., Ltd. · KRX:034940US$6.59MUS$6.89Mn/a0.1×n/a0.3×−4.6%0.1×n/a
Median of the othersUS$12.30MUS$12.81M18.4×0.6×4.6×0.6×1.5%0.1×1.08

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
6.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.18 · 1 analyst
Revenue, year to Dec 2026
46.15M · 2 analysts

Team and board

Officers

OfficerRole
Hermann LuebbertCEO & Chairman
Fred LefflerChief Financial Officer
Daniel HakanssonSenior Corporate Counsel
Erica GatesVice President of Finance
Jon LyonsVice President of Scientific & Medical Affairs
Samantha WiddicombeSenior Vice President of Sales & Strategic Accounts
Wiebke Meyer-WendtVice President of Global Quality & Research
George JonesChief Commercial Officer

Board

DirectorRole
Hermann LuebbertCEO & Chairman
Heikki LanckrietBoard Member
John J. BorerBoard Member
Kevin D. WeberBoard Member

Events

Calls

CallWhenStatus
Biofrontera (NASDAQ:BFRI) Q3 2026 Earnings CallFri, Nov 13, 2026 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2026 Earnings CallThu, Aug 13, 2026 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q1 2026 Earnings CallThu, May 14, 2026 · 11:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q4 2025 Earnings CallThu, Mar 19, 2026 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q3 2025 Earnings CallThu, Nov 13, 2025 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2025 Earnings CallThu, Aug 14, 2025 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q1 2025 Earnings CallFri, May 16, 2025 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q4 2024 Earnings CallFri, Mar 21, 2025 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q3 2024 Earnings CallThu, Nov 14, 2024 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2024 Earnings CallThu, Aug 15, 2024 · 10:00 AM ETReplay
All 22 calls
CallWhenStatus
Biofrontera (NASDAQ:BFRI) Q1 2024 Earnings CallThu, May 16, 2024 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q4 2023 Earnings CallFri, Mar 08, 2024 · 4:30 PM ETReplay
Biofrontera (NASDAQ:BFRI) Q3 2023 Earnings CallFri, Nov 10, 2023 · 10:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2023 Earnings CallFri, Aug 11, 2023 · 8:30 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q1 2023 Earnings CallFri, May 12, 2023 · 8:30 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q4 2022 Earnings CallWed, Mar 08, 2023 · 4:30 PM ETReplay
Biofrontera (NASDAQ:BFRI) Q3 2022 Earnings CallMon, Nov 14, 2022 · 11:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2022 Earnings CallFri, Aug 12, 2022 · 11:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q1 2022 Earnings CallFri, May 13, 2022 · 11:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q4 2021 Earnings CallFri, Apr 08, 2022 · 11:00 AM ETReplay
Biofrontera (NASDAQ:BFRI) Q3 2021 Earnings CallTue, Nov 30, 2021 · 4:30 PM ETReplay
Biofrontera (NASDAQ:BFRI) Q2 2021 Earnings CallFri, Aug 20, 2021 · 4:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open−24.4%
Q2 2026Aug 13, 2026 · Before open+0.8%
Q1 2026May 14, 2026−16.7%
Q4 2025Mar 19, 2026 · After close+1.7%
Q3 2025Nov 12, 2025 · After close−8.6%
Q2 2025Aug 13, 2025 · After close+1.7%
Q1 2025May 15, 2025 · After close−7.2%
Q4 2024Mar 13, 2025 · After close−1.5%
Q3 2024Nov 13, 2024 · After close−15.4%
Q2 2024Aug 14, 2024 · After close+1.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close−9.9%
Q4 2023Mar 15, 2024 · After close−18.7%
Q3 2023Nov 9, 2023 · After close−2.6%
Q2 2023Aug 11, 2023 · Before open−3.8%
Q1 2023May 12, 2023 · After close+0.5%
Q4 2022Mar 8, 2023 · After close−10.2%
Q3 2022Nov 14, 2022 · Before open0.0%
Q2 2022Aug 12, 2022 · Before open+2.9%
Q1 2022Apr 8, 2022 · Before open+14.4%
Quarter to Sep 30, 2021Nov 30, 2021 · Before open−15.6%

Open Events

Financings

RaiseDate
Private placement of investment
Closed: US$11M raised
Buyers: Rosalind Advisors, Inc. (Co-led the $11 million investment); AIGH Capital Management LLC (Co-led the $11 million investment)
Use of proceeds: Funding the purchase of all U.S. Ameluz and RhodoLED assets from Biofrontera AG
Oct 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a unit on Oct 28, 2021.

Price
US$5.00 a unit
Units offered
3,600,000 units
Offering size
US$18 million
Underwriters' option
Up to 540,000 more units
Listing
BFRI on the Nasdaq Capital Market
Underwriters
Roth Capital Partners, The Benchmark Company · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 7, 2021
Filed publiclyJul 6, 2021
Amended 11 timesNewest Oct 26, 2021
Shares registered with an exchangeOct 20, 2021
Declared effective by the SECOct 28, 2021
Final prospectus, with the priceNov 1, 2021

Filings

FilingFiled
424B4 · ProspectusNov 1, 2021
FWP · Free writing prospectusOct 29, 2021
EFFECT · Notice that a registration is effectiveOct 28, 2021
CERT · Exchange's certificate of listingOct 28, 2021
8-A12B/A · Registration of shares for listing on an exchange, amendedOct 27, 2021
CORRESP · Letter to the SECOct 27, 2021
CORRESP · Letter to the SECOct 27, 2021
S-1/A · Registration statement, amendedOct 26, 2021
CORRESP · Letter to the SECOct 20, 2021
CORRESP · Letter to the SECOct 20, 2021
All 50 filings
FilingFiled
8-A12B · Registration of shares for listing on an exchangeOct 20, 2021
S-1/A · Registration statement, amendedOct 19, 2021
CORRESP · Letter to the SECOct 18, 2021
CORRESP · Letter to the SECOct 18, 2021
S-1/A · Registration statement, amendedOct 15, 2021
CORRESP · Letter to the SECOct 14, 2021
UPLOAD · Letter from the SECOct 14, 2021
S-1/A · Registration statement, amendedOct 14, 2021
CORRESP · Letter to the SECOct 13, 2021
CORRESP · Letter to the SECOct 13, 2021
CORRESP · Letter to the SECOct 13, 2021
S-1/A · Registration statement, amendedOct 13, 2021
UPLOAD · Letter from the SECOct 12, 2021
S-1/A · Registration statement, amendedOct 12, 2021
CORRESP · Letter to the SECOct 8, 2021
CORRESP · Letter to the SECOct 8, 2021
CORRESP · Letter to the SECOct 8, 2021
UPLOAD · Letter from the SECOct 7, 2021
FWP · Free writing prospectusOct 1, 2021
S-1/A · Registration statement, amendedOct 1, 2021
S-1/A · Registration statement, amendedSep 16, 2021
CORRESP · Letter to the SECSep 15, 2021
UPLOAD · Letter from the SECSep 9, 2021
S-1/A · Registration statement, amendedAug 31, 2021
CORRESP · Letter to the SECAug 30, 2021
UPLOAD · Letter from the SECAug 20, 2021
S-1/A · Registration statement, amendedAug 12, 2021
CORRESP · Letter to the SECAug 11, 2021
UPLOAD · Letter from the SECAug 2, 2021
S-1/A · Registration statement, amendedJul 26, 2021
CORRESP · Letter to the SECJul 23, 2021
UPLOAD · Letter from the SECJul 19, 2021
CORRESP · Letter to the SECJul 6, 2021
S-1 · Registration statementJul 6, 2021
UPLOAD · Letter from the SECJul 1, 2021
DRS/A · Draft registration statement, amendedJun 22, 2021
DRSLTR · Letter to the SEC with a draftJun 21, 2021
UPLOAD · Letter from the SECJun 10, 2021
DRS/A · Draft registration statement, amendedMay 11, 2021
DRS · Draft registration statementMay 7, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue41.7M37.3M34.1M28.7M24.1M18.8M26.2M
Cost of revenue8.90M18.6M17.4M15.2M12.7M9.07M12.4M
Gross profit32.8M18.7M16.6M13.5M11.4M9.78M13.8M
Research and development3.72M2.09M77.0K0
Selling, general and administrative37.8M33.8M39.0M35.1M36.5M17.7M28.7M
Operating income-11.3M-17.2M-22.7M-18.6M-25.2M-9.61M-14.9M
Depreciation and amortization138.0K421.0K600.0K101.0K122.0K144.0K667.0K
EBITDA-11.2M-16.8M-22.1M-18.5M-25.1M-9.46M-14.3M
Interest expense452.0K2.11M220.0K12.0K344.0K2.87M2.16M
Income before tax-10.5M-17.7M-20.1M-608.0K-37.7M-10.9M-10.9M
Income tax25.0K22.0K14.0K32.0K56.0K64.0K33.0K
Net income-10.5M-17.8M-20.1M-640.0K-37.7M-11.0M-11.0M
Earnings per share, basic-1.04-3.22-13.02-0.61-4.28-479.48-18.09
Earnings per share, diluted-1.04-3.22-13.02-0.61-4.28-479.48

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents6.39M5.91M1.34M17.2M24.5M8.08M7.30M
Short-term investments9.00K7.00K78.0K10.5M0
Receivables7.29M5.32M5.16M7.41M3.78M3.29M4.79M
Inventory1.43M6.65M10.9M7.17M4.46M7.09M10.5M
Current assets18.1M20.7M23.1M43.1M46.4M19.6M23.5M
Property, plant and equipment2.16M80.0K134.0K204.0K267.0K370.0K503.0K
Total assets28.6M22.1M27.9M50.9M53.2M24.1M28.8M
Accounts payable1.85M1.86M8.91M1.28M658.0K176.0K7.81M
Current liabilities11.9M12.0M18.1M20.9M13.8M4.42M11.7M
Long-term debt4.59M4.10M38.2M
Total debt6.16M4.92M5.40M1.35M38.2M
Total liabilities18.1M17.7M23.1M27.0M41.9M18.3M58.9M
Shareholders' equity10.5M4.43M4.79M23.9M11.3M5.83M-30.2M
Shares outstanding11.6M8.87M1.52M1.33M17.1M8.00M607.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-13.4M-10.3M-24.9M-16.2M-26.7M-12.4M-37.7M
Capital spending-2.00K-10.0K-5.00K-38.0K-11.0K-11.0K-538.0K
Free cash flow-13.4M-10.3M-24.9M-16.2M-26.7M-12.4M-38.2M
Cash from investing3.00M-3.00K619.0K-5.16M-11.0K-11.0K25.4M
Cash from financing10.8M14.8M8.41M14.0M43.2M13.2M16.4M
Change in cash487.0K4.56M-15.9M-7.33M16.5M825.0K4.12M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 13, 2026ResultsSEC
25-NSEOct 30, 2026Other filingsSEC
8-K · Current reportSep 14, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 29, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJul 22, 2026Offer documentSEC
10-K/A · Annual report, amendedJul 22, 2026Annual reportSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
8-K · Current reportMar 9, 2026Current reportSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2026Big-stake noticeSEC
8-K · Current reportJan 13, 2026ResultsSEC
8-K · Current reportJan 7, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveDec 22, 2025Other filingsSEC
CORRESP · Letter to the SECDec 17, 2025Other filingsSEC
S-1 · Registration statementDec 5, 2025Offer documentSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
8-K · Current reportNov 10, 2025Current reportSEC
8-K · Current reportNov 7, 2025Acquisition or disposalSEC
8-K · Current reportOct 24, 2025Acquisition or disposalSEC
8-K · Current reportOct 23, 2025Current reportSEC
3 · Initial statement of ownershipSep 30, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 30, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 30, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 30, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 26, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 26, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2025Insider tradeSEC
8-K · Current reportSep 19, 2025Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 19, 2025Big-stake noticeSEC
4 · Change in ownershipSep 18, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 20, 2025Other filingsSEC
CORRESP · Letter to the SECAug 15, 2025Other filingsSEC
S-1/A · Registration statement, amendedAug 13, 2025Offer documentSEC
8-K · Current reportAug 13, 2025ResultsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2025Big-stake noticeSEC
DEF 14A · Proxy statementAug 5, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 25, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 25, 2025Big-stake noticeSEC
S-1 · Registration statementJul 16, 2025Offer documentSEC
8-K/A · Current report, amendedJul 16, 2025Current reportSEC
DJul 11, 2025Other filingsSEC
3 · Initial statement of ownershipJul 9, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Material contractSEC
8-K · Current reportJun 30, 2025Current reportSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
8-K · Current reportJun 11, 2025Current reportSEC
8-K · Current reportJun 3, 2025Current reportSEC
DEFR14AJun 3, 2025Meeting noticeSEC
8-K · Current reportMay 23, 2025Current reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
8-K · Current reportApr 18, 2025Current reportSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
8-K · Current reportMar 21, 2025ResultsSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 29, 2025Other filingsSEC
CORRESP · Letter to the SECJan 24, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 22, 2025Other filingsSEC
S-1 · Registration statementJan 21, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 20, 2024Big-stake noticeSEC
DDec 5, 2024Other filingsSEC
8-K · Current reportNov 27, 2024Material contractSEC
8-K · Current reportNov 22, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
S-8 · Registration statement for employee plansNov 13, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 1, 2024Big-stake noticeSEC
8-K · Current reportOct 31, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 23, 2024Big-stake noticeSEC
8-K · Current reportOct 7, 2024Current reportSEC
SC 13G · Big-stake noticeSep 12, 2024Big-stake noticeSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
8-K · Current reportJun 24, 2024Current reportSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedMay 29, 2024Big-stake noticeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
8-K · Current reportMay 22, 2024Current reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 10, 2024Other filingsSEC
CORRESP · Letter to the SECMay 8, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 8, 2024Other filingsSEC
SC 13G · Big-stake noticeMay 7, 2024Big-stake noticeSEC
8-K · Current reportMay 3, 2024Current reportSEC
S-1 · Registration statementMay 2, 2024Offer documentSEC
8-K · Current reportApr 30, 2024Current reportSEC
DEFR14AApr 30, 2024Meeting noticeSEC
8-K · Current reportApr 25, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveApr 23, 2024Other filingsSEC
CORRESP · Letter to the SECApr 22, 2024Other filingsSEC
DEF 14A · Proxy statementApr 17, 2024Meeting noticeSEC
8-K/A · Current report, amendedApr 3, 2024Current reportSEC
8-K · Current reportMar 26, 2024Current reportSEC
SC 13G · Big-stake noticeMar 21, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMar 20, 2024Big-stake noticeSEC
DEF 14A · Proxy statementMar 20, 2024Meeting noticeSEC
SC 13G · Big-stake noticeMar 20, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMar 20, 2024Big-stake noticeSEC
S-1/A · Registration statement, amendedMar 19, 2024Offer documentSEC
UPLOAD · Letter from the SECMar 18, 2024Other filingsSEC
8-K · Current reportMar 15, 2024ResultsSEC
10-K · Annual reportMar 15, 2024Annual reportSEC
SC 13G · Big-stake noticeMar 15, 2024Big-stake noticeSEC
S-1 · Registration statementMar 8, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementMar 8, 2024Meeting noticeSEC
DMar 5, 2024Other filingsSEC
8-K · Current reportFeb 23, 2024Material contractSEC
8-K · Current reportFeb 20, 2024Material contractSEC
RW · Request to withdraw a registrationFeb 20, 2024Other filingsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024Current reportSEC
8-K · Current reportFeb 5, 2024Current reportSEC
8-K · Current reportFeb 2, 2024Material contractSEC
S-1/A · Registration statement, amendedJan 29, 2024Offer documentSEC
8-K · Current reportJan 25, 2024Current reportSEC
S-1 · Registration statementJan 16, 2024Offer documentSEC
8-K · Current reportJan 11, 2024ResultsSEC
8-K/A · Current report, amendedJan 9, 2024Current reportSEC
8-K · Current reportJan 3, 2024Material contractSEC
8-K · Current reportDec 28, 2023Material contractSEC
8-K · Current reportDec 27, 2023Meeting outcomeSEC
8-K · Current reportDec 15, 2023Material contractSEC
8-K · Current reportNov 29, 2023Current reportSEC
DEF 14A · Proxy statementNov 17, 2023Meeting noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportNov 2, 2023Material contractSEC
424B4 · ProspectusNov 1, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 31, 2023Other filingsSEC
CORRESP · Letter to the SECOct 27, 2023Other filingsSEC
S-1/A · Registration statement, amendedOct 26, 2023Offer documentSEC
CORRESP · Letter to the SECOct 13, 2023Other filingsSEC
S-1/A · Registration statement, amendedOct 13, 2023Offer documentSEC
8-K · Current reportOct 13, 2023Material contractSEC
UPLOAD · Letter from the SECOct 11, 2023Other filingsSEC
8-K · Current reportOct 10, 2023Current reportSEC
S-1 · Registration statementOct 4, 2023Offer documentSEC
8-K · Current reportOct 4, 2023ResultsSEC
8-K · Current reportOct 3, 2023Current reportSEC
3 · Initial statement of ownershipAug 22, 2023Insider tradeSEC
8-K · Current reportAug 11, 2023ResultsSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportJul 13, 2023ResultsSEC
8-K · Current reportJul 12, 2023Management or board changeSEC
8-K · Current reportJul 3, 2023Current reportSEC
8-K · Current reportJun 20, 2023Current reportSEC
8-K · Current reportJun 2, 2023Current reportSEC
8-K · Current reportJun 1, 2023Current reportSEC
8-K · Current reportMay 30, 2023Current reportSEC
8-K · Current reportMay 26, 2023Management or board changeSEC

This page holds 200 of 369 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Biofrontera Inc.’s releases · as of Nov 11, 2026

Common shares
17,949,000
Fully diluted
17,949,000

Fully diluted

LineSharesAs of
Common shares17,949,000Nov 11, 2026

Share count over time

CountShares
Nov 11, 202617,949,000
Sep 30, 202617,949,000

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Rosalind Advisors, Inc.1.79M10.0%US$1.93MSep 30, 2026
AIGH Capital Management LLC1.5M8.3%US$1.62MSep 30, 2026
Renaissance Technologies661K3.7%US$714KSep 30, 2026
Vanguard183K1.0%US$198KSep 30, 2026
Acadian Asset Management LLC164K0.92%US$177KSep 30, 2026
Jane Street116K0.65%US$126KSep 30, 2026
Geode Capital111K0.62%US$119KSep 30, 2026
Hrt Financial LP42,0420.23%US$45,000Sep 30, 2026
Virtu Financial LLC40,9690.23%US$44,000Sep 30, 2026
Northern Trust31,5360.18%US$34,059Sep 30, 2026
All 19 holders
HolderSharesOf the companyValueAs of
XTX Topco Ltd28,8860.16%US$31,197Sep 30, 2026
Citigroup Inc26,6680.15%US$28,801Sep 30, 2026
Susquehanna14,8720.08%US$16,062Sep 30, 2026
Jones Financial Companies Lllp10,0000.06%US$11,800Sep 30, 2026
Tower Research Capital LLC (TRC)6,2620.03%US$6,763Sep 30, 2026
UBS5,4610.03%US$5,898Sep 30, 2026
BlackRock4,6220.03%US$4,992Sep 30, 2026
SBI Securities Co., Ltd.323<0.01%US$349Sep 30, 2026
Caitong International Asset Management Co., Ltd7<0.01%US$8Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund77,0680.43%US$68,282May 31, 2026
Vanguard Extended Market Index Fund71,3800.40%US$67,490Jun 30, 2026
Fidelity Series Total Market Index Fund7,4880.04%US$6,634May 31, 2026
Fidelity Total Market Index Fund422<0.01%US$374May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Deutsche Balaton Aktiengesellschaft19.99%2.55MSep 16, 2025Schedule 13D
Rosalind Advisors, Inc.9.90%15.9MSep 30, 2026Schedule 13G
Orin Hirschman7.90%915KDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Beth J HoffmanDirector · Since at least Nov 2, 2021
Daniel HakanssonSenior Corporate Counsel · Since at least Nov 5, 2026
Erica GatesVice President of Finance · Since at least Nov 5, 2026
Eugene Frederick LefflerChief Financial Officer · Since at least Jul 12, 2024
Fred LefflerChief Financial Officer · Since at least Aug 13, 2026
George JonesChief Commercial Officer · Since at least Aug 11, 2025
Heikki LanckrietBoard Member · Since at least Jul 3, 2023
Hermann LuebbertCEO & Chairman · Since at least Jul 22, 2025
John J. BorerBoard Member · Since at least Nov 4, 2026
John J Borer IIIDirector · Since at least Nov 2, 2021
All 14 people
PersonSeat
Jon LyonsVice President of Scientific & Medical Affairs · Since at least Nov 4, 2026
Kevin D. WeberBoard Member · Since at least Mar 2, 2022
Samantha WiddicombeSenior Vice President of Sales & Strategic Accounts · Since at least Nov 5, 2026
Wiebke Meyer-WendtVice President of Global Quality & Research · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Biofrontera Inc.